Table 2.
Nerve conduction results at DCCT baseline and at DCCT completion
| DCCT baseline |
DCCT completion | ||||
|---|---|---|---|---|---|
| All subjects | Subgroup 1 | Subgroup 2 | Subgroup 3 | Subgroup 4 | |
| Attribute/nerve | |||||
| Intensive treatment group | 711 | 647 | 608 | 470 | 361 |
| Conventional treatment group | 730 | 606 | 567 | 330 | 228 |
| Median motor | |||||
| Amplitude (mV) | |||||
| Intensive treatment group | 10.4 ± 4.1 | 10.4 ± 3.5 | 10.5 ± 3.6 | 10.7 ± 3.6 | 10.7 ± 3.7 |
| Conventional treatment group | 10.4 ± 4.0 | 10.4 ± 3.3 | 10.4 ± 3.4 | 10.7 ± 3.3 | 10.9 ± 3.4 |
| CV (m/s) | |||||
| Intensive treatment group | 54.0 ± 4.6 | 55.0 ± 4.1* | 55.0 ± 4.1* | 55.7 ± 3.5* | 55.8 ± 3.5* |
| Conventional treatment group | 53.8 ± 4.5 | 52.9 ± 4.6 | 52.9 ± 4.6 | 54.4 ± 3.7 | 54.4 ± 3.7 |
| F-wave latency (ms) | |||||
| Intensive treatment group | 28.2 ± 2.8 | 27.7 ± 2.6* | 27.7 ± 2.6* | 27.3 ± 2.4 | 27.3 ± 2.5 |
| Conventional treatment group | 28.2 ± 2.7 | 28.8 ± 2.9 | 28.8 ± 2.9 | 27.5 ± 2.2 | 27.4 ± 2.2 |
| Median sensory | |||||
| Amplitude (±V) | |||||
| Intensive treatment group | 21.3 ± 13.3 | 18.9 ± 13.7 | 18.8 ± 13.3 | 20.2 ± 13.4 | 20.4 ± 13.5 |
| Conventional treatment group | 22.3 ± 13.6 | 17.8 ± 12.4 | 17.6 ± 12.3 | 20.7 ± 12.6 | 21.4 ± 2.2 |
| CV (m/s) | |||||
| Intensive treatment group | 51.4 ± 7.5 | 51.5 ± 7.6† | 51.4 ± 7.7† | 53.0 ± 6.9 | 53.4 ± 6.6 |
| Conventional treatment group | 52.0 ± 7.5 | 50.1 ± 7.6 | 50.0 ± 7.7 | 52.3 ± 6.3 | 52.9 ± 6.3 |
| Peroneal motor | |||||
| Amplitude (mV) | |||||
| Intensive treatment group | 5.8 ± 2.6 | 6.0 ± 2.5* | 6.0 ± 2.5* | 6.3 ± 2.4 | 6.4 ± 2.4 |
| Conventional treatment group | 5.8 ± 2.7 | 5.4 ± 2.6 | 5.4 ± 2.6 | 6.0 ± 2.5 | 6.1 ± 2.5 |
| CV (m/s) | |||||
| Intensive treatment group | 43.6 ± 4.7 | 45.1 ± 4.2* | 45.1 ± 4.2* | 46.0 ± 3.7* | 46.0 ± 3.7* |
| Conventional treatment group | 43.4 ± 4.9 | 42.0 ± 4.8 | 41.9 ± 4.9 | 44.0 ± 3.5 | 44.4 ± 3.5 |
| F-wave latency (ms) | |||||
| Intensive treatment group | 50.6 ± 6.7 | 50.0 ± 5.6* | 50.1 ± 5.6* | 49.1 ± 4.9‡ | 49.2 ± 4.7 |
| Conventional treatment group | 50.8 ± 7.2 | 52.2 ± 6.5 | 52.4 ± 6.6 | 50.1 ± 5.2 | 50.0 ± 4.7 |
| Sural sensory | |||||
| Amplitude (±V) | |||||
| Intensive treatment group | 13.4 ± 8.5 | 12.9 ± 8.6* | 12.9 ± 8.9* | 14.1 ± 8.2 | 14.1 ± 7.2 |
| Conventional treatment group | 14.0 ± 8.7 | 11.3 ± 9.5 | 11.3 ± 9.7 | 13.5 ± 9.1 | 13.9 ± 9.1 |
| CV (m/s) | |||||
| Intensive treatment group | 44.4 ± 6.3 | 45.9 ± 6.1* | 45.9 ± 6.2* | 47.3 ± 5.6‡ | 47.4 ± 5.7 |
| Conventional treatment group | 44.9 ± 6.6 | 43.7 ± 5.9 | 43.7 ± 6.0 | 46.1 ± 5.2 | 46.2 ± 4.9 |
Data are means ± SD. Results for DCCT completion reflect analyses after sequentially excluding subjects with confirmed clinical neuropathy, the primary DCCT neuropathy end point (subgroup 1); definite clinical neuropathy (subgroup 2); possible clinical neuropathy or definite clinical neuropathy (subgroup 3); and possible clinical neuropathy, definite clinical neuropathy, or subclinical neuropathy (subgroup 4). Subgroup 4 represents subjects who did not meet any of the DCCT definitions of clinical or subclinical neuropathy. CV, conduction velocity.
*
P ± 0.0001;
†
P ± 0.001;
‡
P ± 0.01.